{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221658","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2026-05-13T20:15:17+00:00","discovered_at":"2026-05-13T20:16:00.479679+00:00","generated_at":"2026-05-13T20:16:22.801620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial","bullets":["Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.","Net loss $39.0M ($0.33/share) vs $6.5M ($0.08/share) in Q1 2025; includes $19M non-cash loss from warrant liabilities.","R&D expense $17.2M (incl. $1.1M stock comp) vs $13.5M in prior year; G&A $4.0M vs $4.4M.","10/10 evaluable patients achieved 100% insulin independence with tegoprubart in islet transplantation; no rejection or tacrolimus-like toxicities.","FDA granted Orphan Drug designation for tegoprubart in liver transplantation; Phase 3 kidney trial design guidance expected from FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221658","json":"https://secwatch.observer/filing/0001193125-26-221658.json","markdown":"https://secwatch.observer/filing/0001193125-26-221658.md","text":"https://secwatch.observer/filing/0001193125-26-221658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/0001193125-26-221658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:16:22.801620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}